ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients
Autor: | Andrea Picchianti-Diamanti, Alessandra Aiello, Bruno Laganà, Chiara Agrati, Concetta Castilletti, Silvia Meschi, Chiara Farroni, Daniele Lapa, Saeid Najafi Fard, Gilda Cuzzi, Eleonora Cimini, Germana Grassi, Valentina Vanini, Roberta Di Rosa, Simonetta Salemi, Gabriele Nalli, Andrea Salmi, Federica Repele, Anna Maria Gerarda Altera, Gaetano Maffongelli, Claudia Palazzolo, Serena Vita, Sara Leone, Vincenzo Puro, Maria Rosaria Capobianchi, Giuseppe Ippolito, Emanuele Nicastri, Delia Goletti |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
CD4-Positive T-Lymphocytes
Male rheumatoid arthritis medicine.medical_specialty COVID-19 Vaccines T-Lymphocytes medicine.medical_treatment Immunology Antibodies Viral Serology Arthritis Rheumatoid Interferon-gamma Immune system Internal medicine medicine Humans Immunology and Allergy Lymphocyte Count Adverse effect Aged Original Research Vaccines Synthetic biology SARS-CoV-2 DMARD (disease modifying anti-rheumatic drug) business.industry whole blood COVID-19 Immunotherapy antibody response Middle Aged RC581-607 covid-19 mrna vaccine t cell response dmard (disease modifying anti-rheumatic drug) biological therapy medicine.disease T cell response Rheumatology Vaccination mRNA vaccine Rheumatoid arthritis Spike Glycoprotein Coronavirus biology.protein Female Antibody Immunologic diseases. Allergy business |
Zdroj: | Frontiers in Immunology, Vol 12 (2021) Frontiers in Immunology |
ISSN: | 1664-3224 |
Popis: | ObjectiveTo assess in rheumatoid arthritis (RA) patients, treated with different immunosuppressive therapies, the induction of SARS-CoV-2-specific immune response after vaccination in terms of anti-region-binding-domain (RBD)-antibody- and T-cell-specific responses against spike, and the vaccine safety in terms of clinical impact on disease activity.MethodsHealth care workers (HCWs) and RA patients, having completed the BNT162b2-mRNA vaccination in the last 2 weeks, were enrolled. Serological response was evaluated by quantifying anti-RBD antibodies, while the cell-mediated response was evaluated by a whole-blood test quantifying the interferon (IFN)-γ-response to spike peptides. FACS analysis was performed to identify the cells responding to spike stimulation. RA disease activity was evaluated by clinical examination through the DAS28crp, and local and/or systemic clinical adverse events were registered. In RA patients, the ongoing therapeutic regimen was modified during the vaccination period according to the American College of Rheumatology indications.ResultsWe prospectively enrolled 167 HCWs and 35 RA patients. Anti-RBD-antibodies were detected in almost all patients (34/35, 97%), although the titer was significantly reduced in patients under CTLA-4-inhibitors (median: 465 BAU/mL, IQR: 103-1189, p+ and CD8+ T cells. Finally, no significant increase in disease activity was found in RA patients following vaccination.ConclusionThis study showed for the first time that antibody-specific and whole-blood spike-specific T-cell responses induced by the COVID-19 mRNA-vaccine were present in the majority of RA patients, who underwent a strategy of temporary suspension of immunosuppressive treatment during vaccine administration. However, the magnitude of specific responses was dependent on the immunosuppressive therapy administered. In RA patients, BNT162b2 vaccine was safe and disease activity remained stable. |
Databáze: | OpenAIRE |
Externí odkaz: |